• 1
    Laboratory Center for Disease Control HC. Statistics Canada, Canadian Institute for Health Information, Canadian Cardiovascular Society, Canadian Stroke Society, et al. The changing face of heart disease and stroke in Canada 2000. Ottawa: Heart and Stroke Foundation of Canada, 1999.
  • 2
    Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 13839.
  • 3
    Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. NEJM 1996; 335: 10019.
  • 4
    The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. NEJM 1998; 339: 134957.
  • 5
    Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998; 279: 161522.
  • 6
    Sheperd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. NEJM 1995; 333: 13017.
  • 7
    Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285: 17118.
  • 8
    Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals. Lancet 2002; 360: 722.
  • 9
    Severs PS, Dahlof B, Poulter NR, et al. for the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 2003; 361: 114958.
  • 10
    Genest J. Frohlich J, Fodor G, McPherson R, (the Working Group on Hypercholesterolemia and other Dyslipidemias). CMAJ 2003; 169: 9214.
  • 11
    Andrade SE, Walker AM, Gottlieb LK, et al. Discontinuation of antihyperlipidemic drugs – Do rates reported in clinical trials reflect rates in primary care settings? NEJM 1995; 332: 112531.
  • 12
    Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Australia 1996; 164: 20811.
  • 13
    Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA 1998; 279: 145862.
  • 14
    Eriksson M, Hadell K, Holme I, et al. Adherence with and efficacy of treatment with pravastatin and cholestyramine: a randomized study on lipid lowering in primary care. J Intern Med 1998; 243: 37380.
  • 15
    Jackevicius , CA, Mamdani M, Et Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002; 288: 4627.
  • 16
    Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002; 288: 45561.
  • 17
    Grover SA, Abrahamowicz M, Joseph L, Brewer C, Coupal L, Suissa S. The benefits of treating hyperlipidemia to prevent coronary heart disease: Estimating changes in life expectancy and morbidity. JAMA 1992; 267: 81622.
  • 18
    Grover SA, Coupal L, Paquet S, Zowall H. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events. Arch Intern Med 1999; 159: 593600.
  • 19
    World Health Organization. International classification of diseases. Manual of the international statistical classification of diseases, injuries, and cause of death. 9th revision. Geneva, Switzerland: World Health Organization, 1977 (Publication no. PHS 80–1260).
  • 20
    Statistics Canada Health Division. Canadian classification of diagnostic, therapeutic, and surgical procedures, 2nd edn. Ottawa: Supply and Services, 1986.
  • 21
    Régie l’Assurance Maladie du Québec. Health Ministry, Government of Québec, Québec: Régie de l’Assurance Maladie du Québec; Québec 1997.
  • 22
    Moride Y, Abenhaim L. The depletion of susceptible effects in non-experimental pharmacoepidemiologic research. J Clin Epidemiol 1994; 47: 7317.
  • 23
    Tamblyn R, Lavoie G, Petrella L, et al. The use of prescription claims database in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 1995; 48: 9991009.
  • 24
    Wang PS, Bohn RL, Knight E, et al. Noncompliance with antihypertensive medications. The impact of depressive symptoms and psychosocial factors. J Gen Intern Med 2002; 17: 50411.
  • 25
    Di Matteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: Meta-analysis of the effect of anxiety and depression on patient adherence. Arch Intern Med 2000; 160: 21017.
  • 26
    Kalbfleisch JP, Prentice RL, eds. The Statistical Analysis of Failure Time Data, Second Edition. John Wiley & Sons, 1980.
  • 27
    Greene WH. Econometric analysis, 3rd edn. Upper Saddle River (NJ): Prentice Hall, 1997: p. 552.
  • 28
    Belsley DA, Kuy E, Welsch RE. Regression diagnostics: identifying influential data and sources of collinearity. New York: John Wiley & Sons, 1981.
  • 29
    Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stoke: systematic review and meta-analysis. BMJ 2003; 326: 14239.
  • 30
    Ballantyne CM, Corsini A, Davidson MH, et al. Risk of myopathy with statin therapy in high-risk patients. Arch Internmed 2003; 163: 55364.
  • 31
    Heeschen C, Hamm CW, Laufs U, et al. On behalf on the Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) investigators. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002; 105: 144652.
  • 32
    Bybee KA, Wright RS, Williams BA, et al. Effect of concomitant or very early statin administration on in-hospital mortality and reinfarction in patients with acute myocardial infarction. Am J Cardiol 2001; 87: 7714.
  • 33
    Aronow HD, Topol EJ, Roe MT, et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet 2001; 357: 10638.
  • 34
    Stenestrand U, Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001; 285: 4306.
  • 35
    Perreault S, Lamarre D, Blais L, et al. Persistence and determinants of antihypertensive agents among newly treated middle-aged patients. Pharmacoepidemil Drug Safety 2003; 12 (Suppl 1): S102.
  • 36
    Monane M, Bohn RL, Gurwitz JH, et al. Non compliance with congestive heart failure therapy in the elderly. Arch Intern Med 1994; 154: 210910.
  • 37
    Paganini-Hill A, Ross RK. Reliability of recall of drug usage and other health-related information. Am J Epidemiol 1982; 116: 11422.
  • 38
    Rothman KJ, Greenland S. Precision and Validity in Epidemiologic Studies. Modern Epidemiology. Philadelphia: Lippincott-Raven, 1998: 11534.
  • 39
    Tilley BC, Barnes AB, Bergstralh E, Labarthe D, Noller KL, Colton T, et al. A comparison of pregnancy history recall and medical records. Implications for retrospective studies. Am J Epidemiol 1985; 121: 26981.
  • 40
    Van den Brandt PA, Petri H, Dorant E, Goldbohm RA, Van de Crommert S. Comparison of questionnaire information and pharmacy data on drug use. Pharm Weekbl [Sci] 1991; 13: 916.
  • 41
    West SL, Savitz DA, Koch G, Strom BL, Guess HA, Hartzema A. Recall accuracy for prescription medications: self-report compared with database information. Am J Epidemiol 1995; 142: 110312.
  • 42
    McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions. JAMA 2002; 288: 286879.
  • 43
    Lewis R, Dixon J. Rethinking management of chronic diseases. BMJ 2004; 328: 2202.
  • 44
    Wagner EH. Chronic disease care. Insights from managed care in the United States will help the NHS. BMJ 2004; 328: 1778.
  • 45
    Dixon J, Lewis R, Rosen R, et al. Can the NHS learn from US-managed care organisations? BMJ 2004; 328: 2235.
  • 46
    Bodenheimer T, Lorig K, Holdman H, et al. Patient self-management of chronic disease in primary care. JAMA 2002; 288: 246975.
  • 47
    Wagner EH, Grumbach K. Improving primary care for patients with chronic illness. The Chronic Care Model, Part 2 JAMA 2002; 288: 190914.
  • 48
    Bodenheimer T, Wagner EH, Grumback K. Improving primary care for patients with chronic illness. JAMA 2002; 288: 17759.